Ifn- is currently being tested for the treatment of a wide range of diseases including autoimmune and infectious diseases, solid tumors and hematologic malignancies. as with other biological response modifiers, it is difficult to predict the optimal dose for the desired in vivo effect, and two… More

Medarex has exclusive license to several monoclonal antibodies (mabs) reactive to the high affinity fc receptor for igg (fcgri), on human monocytes. this receptor is a critical trigger molecule for adcc by these cells and has been shown to mediate killing of red cell targets and tumor like cells. we… More

Medarex, inc., has exclusive license to several monoclonal antibodies (mabs) reactive to the high-affinity fc receptor for igg (fc ri), which is expressed on human monocytes and, after ifn activation, on human pmns. this receptor is a critical trigger molecule for adcc by these cells. this research… More

Not Available This program will develop high-power visible laser sources based on frequency conversion of 1 micron diode-pumped solid-state lasers. Improvements are needed in efficient and robust nonlinear materials. The technical objectives of our overall research program are to develop… More

DESCRIPTION (provided by applicant): The long term goal of this proposal is to develop a novel targeted vaccine technology against emerging infectious diseases and pathogens associated with bioterrorism. Previous studies have documented the extremely rapid and potent immune responses elicited by… More